Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study in major depressive ...

Legislation that would give the U.S. government a cut of some big pharma profits has once again surfaced in Congress. First introduced in the 114th Congress and every Congress since, the Medical ...

Following the discussion, attendees will have the opportunity to participate in a live Q&A session, further addressing ...

New York, USA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight DelveInsight’s Allogeneic ...

PRNewswire/ -- "According to the latest BCC Research study, "The global ADCs market is showing a rapid growth trend, with growth rates of 36.5% and 40.7% ...

It is one of the most fundamental questions in science: how can lifeless molecules come together to form a living cell? Bert ...